FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
This article was originally published in The Gray Sheet
In a draft guidance, FDA explains how it plans to communicate signs of postmarket device risks before it has performed a full analysis or developed specific recommendations. Public health advocates say it is a positive move to get ahead of potential safety problems early. The agency is seeking comment from companies on whether it needs to consult with firms prior to releasing information on emerging signals about their devices.
You may also be interested in...
Device firms will have to submit a lot more clinical trials outcomes data to the ClinicalTrials.gov portal – including for products that have not been cleared, approved, or launched – based on a final rule recently issued by HHS. Even though sponsors can delay reporting two years, the rule expands the volume of reports that will find their way to the public-facing, clinical trials website, and the change could have downsides, attorneys say.
Regulatory compliance consulting firm NSF International recently appointed Heather Howell, a former deputy director for communications within US FDA’s device center, to serve as executive VP of training and internal quality management systems for the firm’s medical device group in DC.
FDA’s proposed decision to start giving the public early warning of device risks in its “Emerging Signals” draft was praised by consumer and patient groups in March comments, but industry complained that the agency has no authority to issue early warnings. Companies say the communications will confuse patients and gives firms no chance to review the message FDA sends out about product risks.